MedChunk
Medically reviewed

Treat-to-Target Treatment for Axial Spondyloarthritis

Learn how treat-to-target treatment for axial spondyloarthritis works, including treatment goals, disease activity scores, medications, monitoring, and treatment adjustments.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 13 min read

Treat-to-target treatment for axial spondyloarthritis means setting a clear goal for controlling the disease, checking progress regularly, and adjusting treatment when needed. The main goal is to reduce inflammation and pain, improve movement, and help people stay active. A rheumatologist and patient work together to choose realistic goals and decide whether treatment is working.

How Does Treat-to-Target Treatment Work?

Axial spondyloarthritis (axSpA) is a long-term inflammatory condition that mainly affects the spine and the joints connecting the spine to the pelvis. It includes radiographic axial spondyloarthritis, also called ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Traditional treatment may focus mainly on relieving symptoms. A treat-to-target approach goes further by using an agreed goal to guide ongoing care.

The process generally involves four steps:

  1. Set a treatment target: The patient and rheumatologist agree on a goal, such as very low disease activity or remission.
  2. Measure disease activity: Symptoms, physical function, examination findings, and relevant tests are reviewed.
  3. Assess treatment response: The healthcare team compares current findings with previous results and the agreed target.
  4. Adjust the treatment plan: If inflammation remains active, the rheumatologist may consider changes to medication or other aspects of care.

The Assessment of SpondyloArthritis International Society (ASAS), together with the European Alliance of Associations for Rheumatology (EULAR), recommends guiding axial spondyloarthritis treatment according to a predefined target. Their recommendations also emphasize individualized treatment and shared decision-making.

What Is the Main Treatment Target in Axial Spondyloarthritis?

The preferred long-term goal is remission, meaning that disease activity is very low and inflammation is well controlled. When remission is difficult to achieve, maintaining low disease activity may be a practical alternative.

For many patients, reaching a treatment target means more than reporting less back pain. The healthcare team also considers whether inflammation is controlled and whether daily functioning has improved.

Remission or inactive disease

Remission is the most desirable target because it represents minimal measurable disease activity. However, remission does not necessarily mean the condition has been cured or that all treatment can be stopped.

Some patients may reach remission while continuing medication and exercise. Others may continue to experience symptoms despite treatment.

Low disease activity

Low disease activity means the condition remains present but is controlled to a level considered acceptable for the person's circumstances.

This may be a suitable goal when complete remission is not achievable or when increasing treatment would introduce risks that outweigh the expected benefits.

The Pan American League of Associations for Rheumatology (PANLAR) conditionally recommends a target-based treatment strategy for active axial spondyloarthritis. Its recommendations recognize remission as the preferred goal while considering sustained low disease activity an alternative for many patients. The recommendation also acknowledges limitations in the supporting evidence.

How Do Doctors Measure Progress Toward the Target?

Rheumatologists use structured disease activity assessments alongside medical history, physical examinations, and relevant laboratory or imaging findings.

No single measurement gives a complete picture of disease control.

ASDAS: Ankylosing Spondylitis Disease Activity Score

The Ankylosing Spondylitis Disease Activity Score (ASDAS) is an important tool for measuring disease activity in axial spondyloarthritis.

It combines information about symptoms with a laboratory marker of inflammation, usually C-reactive protein (CRP).

ASDAS considers:

  • Back pain
  • Duration of morning stiffness
  • Peripheral joint pain or swelling
  • The patient's overall assessment of disease activity
  • A blood marker of inflammation, usually CRP

Commonly used ASDAS disease activity categories are:

ASDAS Score Disease Activity Category
Below 1.3 Inactive disease
1.3 to below 2.1 Low disease activity
2.1 to 3.5 High disease activity
Above 3.5 Very high disease activity

These categories help clinicians track changes over time. They are not intended for patients to use as a self-diagnostic tool or as a reason to change medication independently.

BASDAI: Bath Ankylosing Spondylitis Disease Activity Index

The BASDAI is another commonly used assessment tool. It relies on answers to questions about fatigue, pain, tenderness, and stiffness.

Unlike ASDAS, BASDAI does not directly include a blood inflammation marker.

Clinicians may use BASDAI when ASDAS is unavailable or when monitoring treatment under healthcare systems that use BASDAI-based criteria.

Blood tests and imaging

CRP and erythrocyte sedimentation rate (ESR) may help assess inflammation. However, these tests can be normal even when axial spondyloarthritis is active.

MRI can sometimes help identify inflammation in the spine or sacroiliac joints when symptoms and other findings do not clearly establish whether the disease is active.

Repeated MRI scans are not routinely necessary for every follow-up appointment. Imaging is selected according to the clinical situation rather than used automatically to determine treatment success.

Which Treatments Help Patients Reach Their Target?

Treat-to-target care is not one specific medication. It is a strategy that combines appropriate treatments and reviews their effectiveness over time.

Exercise and physical therapy

Regular exercise is a core part of axial spondyloarthritis management, regardless of the medication being used.

A suitable activity program may include:

  • Spinal mobility and stretching exercises
  • Posture exercises
  • Strength training
  • Walking, swimming, or other aerobic activities
  • Individualized physiotherapy when appropriate

According to the National Health Service (NHS), exercise and physiotherapy help support posture and spinal movement and are important alongside medications. These approaches are also used in non-radiographic axial spondyloarthritis.

A physical therapist can help adapt activities to the person's mobility, pain, and physical abilities.

Nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDs are commonly the first medications used to manage pain and inflammation in axial spondyloarthritis.

Examples include naproxen, ibuprofen, and celecoxib.

Doctors consider how well the medicine controls symptoms alongside possible stomach, kidney, and cardiovascular risks. The dose and duration are chosen according to individual needs.

If symptoms remain uncontrolled despite an appropriate NSAID trial, another NSAID or a different treatment approach may be considered.

Biologic medicines

Biologic medicines target parts of the immune system involved in inflammation. They may be considered when disease activity remains high despite appropriate initial treatment.

Two important biologic groups used for axial spondyloarthritis are:

  • TNF inhibitors: Medicines that block tumor necrosis factor, an inflammatory signaling protein. Examples include adalimumab and certolizumab pegol.
  • IL-17 inhibitors: Medicines that block interleukin-17 signaling involved in inflammation. Examples include secukinumab and ixekizumab.

The choice depends on disease activity, previous medication responses, other health conditions, treatment risks, and local prescribing requirements.

JAK inhibitors

Janus kinase (JAK) inhibitors are targeted medicines taken by mouth. They interfere with inflammatory signaling pathways.

They may be considered for selected patients when other treatments are unsuitable or have not provided adequate control.

Because JAK inhibitors have important safety considerations, clinicians assess individual risk factors before prescribing them and monitor patients during treatment.

Conventional disease-modifying medicines such as methotrexate are generally not effective for inflammation limited to the spine. Sulfasalazine may have a role when peripheral joints are affected.

When Should Treatment Be Changed?

Not reaching a treatment target does not automatically mean that a stronger medication is necessary.

Before changing treatment, a rheumatologist reviews whether the ongoing symptoms are caused by active inflammation or another problem.

This distinction matters because persistent pain may also be influenced by existing structural damage, mechanical back problems, or other conditions.

A treatment review may include:

  1. Comparing current disease activity scores with earlier results.
  2. Reviewing symptoms, examination findings, and relevant inflammatory markers.
  3. Checking whether the prescribed treatment is being taken as intended.
  4. Considering side effects, other medical conditions, and alternative causes of pain.
  5. Discussing whether continuing, changing, or switching medication is appropriate.

The American College of Rheumatology (ACR) provides clinical practice guidance for axial spondyloarthritis, including a guideline summary released in June 2026. Treatment decisions should be based on the patient's full clinical assessment and shared decision-making rather than a disease activity score alone.

How Often Is Disease Activity Checked?

The frequency of follow-up depends on how active the disease is, whether treatment has recently changed, and how well symptoms are controlled.

Patients starting a new medication or experiencing ongoing inflammation may need closer monitoring. Those with stable disease may be reviewed less frequently.

After starting certain advanced treatments, rheumatologists commonly assess the response after approximately 12 weeks. This helps determine whether the medicine is producing a meaningful benefit.

A routine appointment may involve discussion of:

  • Back pain and stiffness since the previous visit
  • Fatigue and ability to carry out daily activities
  • Changes in spinal movement or physical function
  • New symptoms involving other joints, eyes, skin, or bowel
  • Medication effectiveness and side effects
  • Blood test results when appropriate

Clinicians may also review spinal mobility and overall health. The aim is to understand whether treatment is controlling inflammation while supporting function and quality of life.

Does Treat-to-Target Work Better Than Usual Care?

Treat-to-target offers a structured way to monitor axial spondyloarthritis, but its benefits over good standard care are not yet fully established.

The TICOSPA clinical trial compared a tightly controlled treat-to-target approach with usual care. The study did not show a statistically significant improvement in its primary outcome, a measure of overall health and functioning, although some secondary outcomes favored treat-to-target care.

This means a strict score-driven strategy has not been proven superior for every patient.

Nonetheless, setting treatment goals and reviewing disease activity remain important parts of clinical care. They help patients and rheumatologists make informed decisions and recognize when a treatment plan may need reassessment.

A target should guide treatment rather than replace clinical judgment.

What Happens After the Treatment Target Is Reached?

Reaching remission or low disease activity is an important achievement, but ongoing monitoring remains necessary.

Axial spondyloarthritis is a chronic condition, and inflammation may return after treatment is reduced or stopped.

For some patients with sustained remission, a rheumatologist may consider carefully reducing the dose or frequency of a biologic medicine. Any reduction should be individualized and monitored.

Stopping treatment completely is generally not the preferred first step because it can increase the likelihood of disease activity returning.

The Mayo Clinic explains that treatment for ankylosing spondylitis focuses on relieving pain and stiffness and helping prevent or delay complications. Medication, physical therapy, and exercise all have roles in long-term management.

Maintaining an exercise routine and attending appropriate follow-up appointments are therefore important even when symptoms have substantially improved.

How Can Patients Take Part in Treat-to-Target Care?

Shared decision-making is central to treat-to-target treatment. Patients can help their healthcare team understand how the condition affects everyday life and what treatment outcomes matter most to them.

Before an appointment, it may be useful to record changes in pain, morning stiffness, fatigue, sleep, physical activity, and medication tolerance.

Helpful questions to discuss with the rheumatologist include:

  • What is my current treatment target?
  • How will we measure whether I am reaching it?
  • Do my symptoms and test results suggest ongoing inflammation?
  • When should we review my current medication?
  • What are the benefits and risks of changing treatment?
  • What should I do if symptoms return between appointments?

It is also important to report persistent worsening symptoms, significant medication side effects, or new health concerns rather than waiting for a scheduled review.

For example, a painful, red eye with sensitivity to light needs prompt medical assessment because inflammatory eye disease can occur in people with axial spondyloarthritis.

Why Individual Treatment Goals Matter

The same target may not be appropriate for every person with axial spondyloarthritis.

Some patients have active inflammation but relatively little structural damage. Others may have lasting stiffness or pain even when current inflammatory activity is low.

Existing health conditions, medication risks, personal priorities, and previous treatment experiences can influence which target is realistic.

For this reason, effective treat-to-target care combines measurable disease activity with the patient's symptoms, daily functioning, and preferences.

The central goal is not simply to achieve a particular score. It is to maintain the best achievable control of inflammation while protecting mobility, physical function, and quality of life.

Frequently Asked Questions

Common questions about treatment goals, monitoring, and long-term care for axial spondyloarthritis.

Can treat-to-target treatment put axial spondyloarthritis into remission?

Remission is a possible treatment goal, and some patients achieve very low or inactive disease activity with appropriate treatment. However, the approach does not guarantee remission or cure the condition. The rheumatologist may recommend sustained low disease activity as an alternative target when appropriate.

What ASDAS score do doctors usually aim for?

An ASDAS score below 1.3 represents inactive disease, while a score from 1.3 to below 2.1 represents low disease activity. These thresholds can help guide treatment discussions. The individual target also depends on symptoms, examination findings, inflammation markers, and other health considerations.

How long does it take to know whether axial spondyloarthritis treatment is working?

The time needed depends on the treatment and the person's response. For many biologic and targeted treatments, a formal response assessment is performed after approximately 12 weeks. Monitoring may begin earlier, and some medicines require different review schedules.

Does a high ASDAS score always mean I need a biologic medicine?

No. A high ASDAS score is one factor in treatment decisions. The rheumatologist also considers whether symptoms reflect active inflammation, the response to previous treatments, relevant test findings, and the benefits and risks of additional medication. A high score alone does not automatically require starting or changing a biologic.

Can I stop medication once my disease activity becomes low?

Low disease activity or remission does not necessarily mean medication can be stopped. Some patients may be able to reduce treatment gradually after sustained remission, but this requires medical supervision. Stopping treatment without consulting the rheumatologist may allow inflammation and symptoms to return.

Citations

  1. Assessment of SpondyloArthritis International Society (ASAS) – ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update
  2. Nature Reviews Rheumatology – Pan American League of Associations for Rheumatology Recommendations for the Management of Axial Spondyloarthritis
  3. National Health Service (NHS) – Ankylosing Spondylitis: Treatment
  4. American College of Rheumatology – Axial Spondyloarthritis Clinical Practice Guidelines
  5. Mayo Clinic – Ankylosing Spondylitis: Diagnosis and Treatment
Share this article